You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

137 search results for: mechanism of disease

IRS-ISIAN 2024 | <b>Mechanism</b>s <b>of</b> Smell Loss in CRSwNP: Blockage and Inflammation

expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

10 min

Rhinology

Prof. Joaquim Mullol examines the mechanisms of smell loss in CRSwNP including the roles of conductive and sensorineural dysfunction.

The Burden <b>of</b> Atopic Dermatitis in Children – The Impact <b>of</b> Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

1 min

Dermatology

Dr. Mark Koh explains how age at disease onset is linked to persistent disease.

ERS 2024 | Unraveling the Role <b>of</b> Type 2 Inflammation in COPD

expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

8 min

Pulmonology

Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.

The <b>Disease</b> Burden <b>of</b> AD in Children and the Impact <b>of</b> Type 2 Comorbidities

expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

12 min

Dermatology

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

ERS 2024 | Understanding the Complex Pathophysiology <b>of</b> COPD

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

The Burden <b>of</b> Atopic Dermatitis in Children – Identifying Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – Identifying Persistent Disease

2 min

Dermatology

Dr. Mark Koh explains how to identify children with persistent disease.

Pathways to <b>Disease</b>: Inflammation in COPD

interactivity

Pathways to Disease: Inflammation in COPD

5 min

Pulmonology

Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways

The Burden <b>of</b> Atopic Dermatitis in Children – Skin Infections and More Severe <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

1 min

Dermatology

Dr. Mark Koh talks about skin infections and their impact on disease severity.

Differences in Manifestations <b>of</b> Type 2 Inflammatory <b>Disease</b>s

expert video

Differences in Manifestations of Type 2 Inflammatory Diseases

2 min

Dermatology

Dr. Brian Kim highlights the differences in manifestation of type 2 inflammatory diseases.

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region